AIFA Board of Directors approves the reimbursability of 13 medicines

News Healthcare & Pharma Sanctions & Fines

Date: 29th Jan, 2025 Source: Italian Medicines Agency (AIFA) Country: Italy Original Source

Brief

"On January 29, 2025, the Italian Medicines Agency (AIFA) Board of Directors approved the reimbursability of 13 medicines. This includes BAQSIMI for severe hypoglycemia in adult and pediatric patients with diabetes mellitus, as well as PLUVICTO for metastatic castration-resistant prostate cancer and ELADYNOS for osteoporosis in postmenopausal women."

This content is restricted.

Highlights content goes here...

This content is restricted.

Italian Medicines Agency (AIFA)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

AIFA Board of Directors approves the reimbursability of 13 medicines

Brief

Italian Medicines Agency (AIFA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

AIFA Board of Directors approves the reimbursability of 13 medicines

Brief

Italian Medicines Agency (AIFA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.